AMAG Pharmaceuticals, Inc. (AMAG) Release: Ferumoxytol Treatment Produced Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Gastrointestinal Disease Who Had Failed or Could Not Tolerate Oral Iron Therapy
5/21/2013 9:03:55 AM
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) Release: Ferumoxytol Results in Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed or Could Not Tolerate Oral Iron Therapy
5/6/2013 9:14:17 AM
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) Announces First Quarter 2013 Financial Results
4/24/2013 7:11:35 AM
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013
4/22/2013 6:25:36 AM
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) Announces Positive Preliminary Results From an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing With Ferumoxytol in Patients With Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause
3/15/2013 10:21:25 AM
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) Announces FDA Acceptance of Supplemental New Drug Application for Feraheme Label Expansion to Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron
3/6/2013 9:53:42 AM
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) Announces Fourth Quarter and Year End 2012 Financial Results
3/1/2013 7:11:32 AM
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) to Present at Upcoming Healthcare Conferences
2/22/2013 6:45:51 AM
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) to Present at the Leerink Swann and Company Global Healthcare Conference
2/8/2013 6:40:23 AM
More...
|
AMAG Pharmaceuticals, Inc. (AMAG) Announces FDA Submission of a Supplemental New Drug Application for Feraheme
12/27/2012 9:21:36 AM
More...
|
|